Skip to main content

Students in leadership positions learn about brain tumors and gain real world experience in running a non-profit business while raising funds for brain tumor research. Beneficiaries of the money we raise are Barrow Neurological Institute, National Brain Tumor Society, Phoenix Children's Hospital, Translational Genomics Research Institute, and University of Arizona.

"Be the change you wish to see in the world..." Gandhi

Our Beneficiaries

  • University of AZ Research Centers
    University of AZ Research Centers
  • “Charity is a supreme virtue, and the great channel through which the mercy of God is passed on to mankind. It is the virtue that unites men and inspires their noblest efforts.”

    — Conrad Hilton

Brain Tumor Research News

Medical researchers from the University of Cambridge have developed two new tests able to detect the presence of glioma, which is a type of brain tumor. The tumor can be detected using the newly developed tests in the urine or blood plasma of the patient. Researchers note that detecting glioma using urine is the first test of its kind in the world.

We’ve seen helmets and AI that can spot brain tumors, but a new hard hat can actually treat them, too. As part of the latest neurological breakthrough, researchers used a helmet that generates a magnetic field to shrink a deadly tumor by a third.

Staff at University of Arkansas for Medical Sciences (UAMS) have performed the state’s first application of GammaTile Therapy. Radiation oncologist Richard Crownover, M.D., Ph.D., and neurosurgeon Analiz Rodriguez, M.D., Ph.D., and their care team successfully embedded the therapy into a patient and veteran from Horseshoe Bend. GammaTile Therapy, marketed by GT Medical Technologies and also known as surgically targeted radiation therapy (STaRT), is designed to delay brain tumor recurrence. It consists of a 3D-collagen tile embedded with a cesium radiation source.

The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest Phase 0 clinical trials program for aggressive brain tumors, announced its plans for a new 75,000-square-foot headquarters, with construction beginning in August. The five-story building will be the largest translational research center dedicated to brain tumor drug development in the world.

A new study indicated that the blood pressure drug losartan may benefit patients with neurofibromatosis type 2 (NF2), a hereditary condition associated with vestibular schwannomas, or noncancerous tumours along the nerves in the brain that are involved with hearing and balance.

Scientists at the University of New Mexico’s Cancer Center are studying brain cancer and why tumors often come back. One local firefighter who knows this all too well, says this kind of research will make a world of difference for patients like him.

View Previous News Articles - Click Here!